Hisamitsu Pharmaceutical Co (TSE:4530) ROCE % : 7.00% (As of Nov. 2023)

View and export this data going back to 1962. Start your Free Trial

What is Hisamitsu Pharmaceutical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Hisamitsu Pharmaceutical Co's annualized ROCE % for the quarter that ended in Nov. 2023 was 7.00%.

Hisamitsu Pharmaceutical Co ROCE % Historical Data

The historical data trend for Hisamitsu Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hisamitsu Pharmaceutical Co ROCE % Chart

Hisamitsu Pharmaceutical Co Annual Data

Trend

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Feb23

Feb24

ROCE %

Get a 7-Day Free Trial

9.84

4.55

4.80

5.95

6.93

Hisamitsu Pharmaceutical Co Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
ROCE %	Get a 7-Day Free Trial															4.44	8.36	8.40	7.00	3.57

Hisamitsu Pharmaceutical Co ROCE % Calculation

Hisamitsu Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Feb. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Feb. 2024 )		(A: Feb. 2023 )		(A: Feb. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Feb. 2024 )		(A: Feb. 2023 )		(A: Feb. 2024 )
	=	19204	/	( ( (313917 - 42578)	+	(328779 - 45938) )	/ 2 )
	=	19204	/	( (271339	+	282841)	/ 2 )
	=	19204	/	277090
	=	6.93 %

Hisamitsu Pharmaceutical Co's ROCE % of for the quarter that ended in Nov. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Nov. 2023 )		(Q: Aug. 2023 )		(Q: Nov. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Nov. 2023 )		(Q: Aug. 2023 )		(Q: Nov. 2023 )
	=	20104	/	( ( (344300 - 54194)	+	(334909 - 50346) )	/ 2 )
	=	20104	/	( ( 290106	+	284563 )	/ 2 )
	=	20104	/	287334.5
	=	7.00 %

(1) Note: The EBIT data used here is four times the quarterly (Nov. 2023) EBIT data.

Hisamitsu Pharmaceutical Co (TSE:4530) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Hisamitsu Pharmaceutical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Hisamitsu Pharmaceutical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hisamitsu Pharmaceutical Co (TSE:4530) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hisamitsu Pharmaceutical Co Inc (TSE:4530) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

HPX:Germany

Address

408 Tashiro Daikan-machi, Tosu, Saga, JPN, 841-0017

Website

http://www.hisamitsu.co.jp

Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.

Hisamitsu Pharmaceutical Co (TSE:4530) Headlines

No Headlines